Patents by Inventor Aleksandr Tkachev

Aleksandr Tkachev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TMEFF1 antibodies and antibody drug conjugates
    Patent number: 11981732
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: May 14, 2024
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF
    Publication number: 20240084032
    Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.
    Type: Application
    Filed: May 19, 2023
    Publication date: March 14, 2024
    Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
  • ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20230331839
    Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 28, 2023
    Publication date: October 19, 2023
    Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
  • Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
    Patent number: 11702481
    Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: July 18, 2023
    Assignee: Bluefin Biomedicine, Inc.
    Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
  • ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20230192885
    Abstract: Disclosed herein are anti-lymphocyte antigen 6 complex, locus H (LY6H) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: July 28, 2022
    Publication date: June 22, 2023
    Inventors: Tinglei Gu, Scott Michael Lonning, Nels Eric Pederson, Aleksandr Tkachev, Klarisa Rikova, Sean A. Beausoleil
  • Anti-SEZ6L2 antibodies and antibody drug conjugates
    Patent number: 11634486
    Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 25, 2023
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
  • ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20220298239
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 22, 2022
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • Anti-LY6H antibodies and antibody drug conjugates
    Patent number: 11434303
    Abstract: Disclosed herein are anti-lymphocyte antigen 6 complex, locus H (LY6H) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: September 6, 2022
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Tinglei Gu, Scott Michael Lonning, Nels Eric Pederson, Aleksandr Tkachev, Klarisa Rikova, Sean A. Beausoleil
  • ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20220227863
    Abstract: Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 21, 2022
    Inventors: Jaime Rene Darce, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev
  • Anti-TMEFF1 antibodies and antibody drug conjugates
    Patent number: 11312769
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 26, 2022
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • Anti-ILT3 antibodies and antibody drug conjugates
    Patent number: 11267886
    Abstract: Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: March 8, 2022
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Jaime Darce, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev
  • ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20210130454
    Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody dmg conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 6, 2021
    Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
  • ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200308298
    Abstract: Disclosed herein are anti-lymphocyte antigen 6 complex, locus H (LY6H) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 1, 2020
    Inventors: Tinglei Gu, Scott Michael Lonning, Nels Eric Pederson, Aleksandr Tkachev, Klarisa Rikova, Sean A. Beausoleil
  • ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF
    Publication number: 20200181281
    Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 11, 2020
    Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
  • ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200109194
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 22, 2018
    Publication date: April 9, 2020
    Applicant: Bluefin BioMedicine, Inc.
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200031926
    Abstract: Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: February 9, 2018
    Publication date: January 30, 2020
    Applicant: Bluefin BioMedicine, Inc.
    Inventors: Jaime Darce, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev